ZME Science
No Result
View All Result
ZME Science
No Result
View All Result
ZME Science

Home → Science

Personalized cancer vaccine shows efficacy against multiple cancers in early tests

Hopefully, future tests will support these findings.

Alexandru MicubyAlexandru Micu
April 12, 2021
in Health, News, Science
A A
Share on FacebookShare on TwitterSubmit to Reddit

A personalized cancer vaccine prototype has shown great promise in a phase 1 trial against different types of cancer, including some that have a high risk of reappearing.

Image credits Arek Socha.

I’m not sure if everybody here is old enough to remember this, but there used to be a time when “finding the cure to cancer” was seen as the be-all-end-all of human ingenuity. Back when my family was still toying with the idea of sending me off to medical school, my grandparents would cheer me on saying that maybe I’ll be the one to discover it — with everybody sharing the silent knowledge that such a wonder would not be possible in our lifetime. So it’s a very surreal experience to see just how far along we’ve come towards that goal.

A new paper reports that personalized vaccines against cancers — compounds created from the genetic data of individual patients and their tumors — are effective against the disease, safe to use, and show promise against commonly recurring cases.

Individually tailored

“While immunotherapy has revolutionized the treatment of cancer, the vast majority of patients do not experience a significant clinical response with such treatments,” said study author Thomas Marron, MD, Ph.D., Assistant Director for Early Phase and Immunotherapy Trials at The Tisch Cancer Institute and Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai.

“Cancer vaccines, which typically combine tumor-specific targets that the immune system, can learn to recognize and attack to prevent recurrence of cancer. The vaccine also contains an adjuvant that primes the immune system to maximize the efficacy.”

This class of vaccines was developed with help from the Mount Sinai computational platform OpenVax, created by a group which “develops open-source software for designing personalized cancer vaccines”. In order to create these personalized vaccines, Dr Marron and his team sequenced tumor and germline DNA, alongside tumor RNA, from each patient. They also used this data to help predict whether each individual’s immune system would recognize the vaccine’s targets or not.

For the trial, the participants received 10 doses of the personalized vaccine over a six-month period after undergoing any standard cancer treatment (for example surgery). It was administered alongside an immunostimulant (or an ‘adjuvant’). This adjuvant, poly-ICLC, is a synthetic, stabilized, double-stranded RNA capable of activating multiple innate immune receptors, making it the optimal adjuvant for inducing immune responses against tumor neoantigens,” said study author Nina Bhardwaj.

Thirteen participants received the prototype vaccine. Out of them, 10 had been diagnosed with solid tumors, and 3 had multiple myeloma. All of them had, statistically speaking, a high chance of seeing a resurgence of the disease following treatment.

However, after a mean follow-up interval of 880 days, four of the participants were still cancer-free, four were receiving subsequent lines of therapy, four had died, and one chose to not continue the trial. The vaccine was tolerated well upon administration, with only one-third of the participants developing minor reactions

RelatedPosts

Radiologists miss out on 7% of cancers – this computer algorithm doesn’t
A component from scorpion and honeybee venom stops cancer growth
The anti-vaccine myths that need to go away
Genetically engineered virus kills liver cancer and significantly prolongs life

“Most experimental personalized cancer vaccines are administered in the metastatic setting, but prior research indicates that immunotherapies tend to be more effective in patients who have less cancer spread,” said Dr. Bhardwaj.

“We have therefore developed a neoantigen vaccine that is administered after standard-of-care adjuvant therapy, […] when patients have minimal — typically microscopic — residual disease. Our results demonstrate that the OpenVax pipeline is a viable approach to generate a safe, personalized cancer vaccine, which could potentially be used to treat a range of tumor types.”

The most exciting area of the finding relates to types of cancer that have a high risk of recurrence, such as lung and bladder cancers. Personalized vaccines could finally give us a safe and efficient means of fighting them, and preventing them from reforming.

Still, these results were from a phase 1 trial, whose main aim is to determine whether a drug candidate is safe to use. While the potential benefits of the compound were noticed, determining how best to administer it for the greatest effect is the object of the phase 2 trial — meaning, we’ll have a good idea of what this vaccine can and can’t do quite soon.

The findings have been presented during Week 1 of the virtual AACR Annual Meeting 2021, held April 10-15.

Tags: cancervaccine

ShareTweetShare
Alexandru Micu

Alexandru Micu

Stunningly charming pun connoisseur, I have been fascinated by the world around me since I first laid eyes on it. Always curious, I'm just having a little fun with some very serious science.

Related Posts

Health

RFK Jr, Nation’s Top Health Official, Refuses to Recommend the Measles Vaccine, Says ‘I Don’t Think People Should Be Taking Medical Advice from Me’

byTudor Tarita
4 days ago
A unique eye accessory
Health

Miracle surgery: Doctors remove a hard-to-reach spinal tumor through the eye of a patient

byRupendra Brahambhatt
2 weeks ago
Health

This Futuristic Laser Blood Test May Be the Key to Beating Cancer Early

byTudor Tarita
1 month ago
Health

CT Scans Save Lives But Researchers Now Say They Could Also Be Behind 100,000 Future Cancer Cases

byTibi Puiu
1 month ago

Recent news

A Hawk in New Jersey Figured Out Traffic Signals and Used Them to Hunt

May 23, 2025

Anthropic’s new AI model (Claude) will scheme and even blackmail to avoid getting shut down

May 23, 2025

Researchers create contact lenses that let you see in the dark, even with your eyes closed

May 23, 2025
  • About
  • Advertise
  • Editorial Policy
  • Privacy Policy and Terms of Use
  • How we review products
  • Contact

© 2007-2025 ZME Science - Not exactly rocket science. All Rights Reserved.

No Result
View All Result
  • Science News
  • Environment
  • Health
  • Space
  • Future
  • Features
    • Natural Sciences
    • Physics
      • Matter and Energy
      • Quantum Mechanics
      • Thermodynamics
    • Chemistry
      • Periodic Table
      • Applied Chemistry
      • Materials
      • Physical Chemistry
    • Biology
      • Anatomy
      • Biochemistry
      • Ecology
      • Genetics
      • Microbiology
      • Plants and Fungi
    • Geology and Paleontology
      • Planet Earth
      • Earth Dynamics
      • Rocks and Minerals
      • Volcanoes
      • Dinosaurs
      • Fossils
    • Animals
      • Mammals
      • Birds
      • Fish
      • Amphibians
      • Reptiles
      • Invertebrates
      • Pets
      • Conservation
      • Animal facts
    • Climate and Weather
      • Climate change
      • Weather and atmosphere
    • Health
      • Drugs
      • Diseases and Conditions
      • Human Body
      • Mind and Brain
      • Food and Nutrition
      • Wellness
    • History and Humanities
      • Anthropology
      • Archaeology
      • History
      • Economics
      • People
      • Sociology
    • Space & Astronomy
      • The Solar System
      • Sun
      • The Moon
      • Planets
      • Asteroids, meteors & comets
      • Astronomy
      • Astrophysics
      • Cosmology
      • Exoplanets & Alien Life
      • Spaceflight and Exploration
    • Technology
      • Computer Science & IT
      • Engineering
      • Inventions
      • Sustainability
      • Renewable Energy
      • Green Living
    • Culture
    • Resources
  • Videos
  • Reviews
  • About Us
    • About
    • The Team
    • Advertise
    • Contribute
    • Editorial policy
    • Privacy Policy
    • Contact

© 2007-2025 ZME Science - Not exactly rocket science. All Rights Reserved.